It looks like Merck CEO Kenneth Frazier is grooming a clone.
The company announced today that Michael J. Holston…
investing.businessweek.com/resea … m%2C%20Inc.
…who’s currently chief ethics and compliance officer, will become general counsel next year, also overseeing Merck’s “communications, policy and security organizations.”
Otherwise put, Merck knows that Propecia is shaping up to be Vioxx Part II, so they want (need) a lawyer to handle areas that lawyers typically do not handle (because their best bet for survival is to fight everything in court, where they can best control the damage–or at least they believe such).
The full story here: